Be Clinical raises ₹21 Cr to scale clinical skincare R&D and manufacturing
The Indian D2C skincare brand secured a Sauce-led seed extension to expand its product portfolio, manufacturing capacity and geographic reach. Be Clinical sells via its website, Amazon and Flipkart, and says it has fulfilled 1.2 lakh orders.
What happened
Indian D2C clinical skincare brand Be Clinical raised ₹21 Cr in a Sauce-led seed extension to expand R&D, manufacturing, product categories and markets. The
Key facts
- ₹21 Cr
- about $2.2 Mn
- 1.2 Lakh orders
- ₹6 Cr prior seed round
- ₹2 Cr earlier funding
- India BPC market: $31.19 Bn in 2025
- India BPC market projected at $48.72 Bn by 2034
- 5.08% CAGR
Why this matters
Be Clinical’s expanding product portfolio and manufacturing capabilities make it a potential partnership or acquisition target for beauty players seeking a clinically positioned Indian skincare brand.
What to watch
- New SKU launches and evidence of category expansion beyond the current core portfolio.
- Manufacturing facility announcements, contract-manufacturing changes or regulatory/quality certifications.
- Order growth, repeat-purchase metrics, average order value and contribution-margin commentary.
- Amazon and Flipkart review counts, ratings, search visibility and discount intensity.
- Follow-on fundraising, major retail distribution partnerships or dermatologist/clinic channel tie-ups.
- Launch additional concern-specific clinical skincare SKUs and regimen bundles.
- Expand manufacturing and quality-control capabilities, likely prioritizing faster product-development cycles.
- Increase marketplace visibility on Amazon and Flipkart while using the D2C site for subscriptions, bundles and customer-data capture.
- Build dermatologist, clinic, creator and performance-marketing partnerships to reinforce clinical positioning.
- Use funding to enter additional Indian cities and potentially test selected international diaspora markets.
Also reported by
- Inc42 · Buzz — Same time